Vigeo

Reprogramming the **tumor immune microenvironment**

WHO WE ARE

Vigeo Therapeutics based in Cambridge, MA, is a clinical-stage biopharmaceutical company developing novel therapeutics that have the potential to treat multiple types of cancer and improve the lives of patients. Vigeo was co-founded by Randolph Watnick, Ph.D., a pioneer in understanding the role of the tumor microenvironment in metastasis, and Jing Watnick, Ph.D., M.B.A., an accomplished research scientist and leader in biopharmaceutical development. To date, the company has raised $27.5M in two financing rounds, both funded by Morningside Ventures.

MANAGEMENT

Jing Watnick, PhD, MBA
President and Chief Executive Officer
Lou Vaickus, MD
Chief Medical Officer
Michael J. Cieslewicz, PhD
Head of Program Management
Daniel Geffken, MBA
Interim Chief Financial Officer
Ruth Adams, BSc
Head of Clinical Operations
Steven Bloom, B Pharm
Strategic Advisor

BOARD OF DIRECTORS

Stephanie O'Brien, JD
Director, Morningside Ventures
Westley Nolin, PhD
Director, Morningside Ventures
James Mahoney, MBA, MMA
Director, Ara Partners
Jing Watnick, PhD, MBA
President and Chief Executive Officer

SCIENTIFIC ADVISORY BOARD

Lars Akslen, MD, PhD
Rolf Brekken, PhD
Napoleone Ferrara, MD
Randolph Watnick, PhD
Robert Weinberg, PhD
Bruce Zetter, PhD

OUR APPROACH

Vigeo has built a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TME) and is the first, and only, company developing therapies designed to stimulate Tsp-1 expression by replicating the biological activity of prosaposin (Psap). Tsp-1 has been shown to inhibit the growth of cancer cells and to prevent their spread through metastasis. We believe that by reprogramming the TME, we can significantly improve cancer treatment outcomes.

OUR LEAD MOLECULE

Vigeo's lead molecule, VT1021, is about to conclude the dose escalation phase of its first in human study and enter the expansion phase in selected tumor types in 2020. The safety and PK profiles of VT1021 have been well established and the clinical response data obtained so far has been promising.

VT1021 is a small peptide agent derived from Psap that triggers Tsp-1 production, reprogramming the tumor microenvironment making it inhospitable for tumor growth to occur. Pre-clinical results have demonstrated that VT1021, when administered systemically, can cause tumor regression in animal models at both the primary and metastatic sites. In the Phase 1/2a clinical study dose-escalation stage, VT1021 has established an excellent safety profile with consistent PK parameters. VT1021 has also exhibited remarkable biomarker activity, as well as durable control of disease progression and clinical response. The expansion phase interim readout is expected in Q3 of 2020. In addition, multiple combination studies have been planned to test the efficacy of VT1021 in combination with other IO agents and chemotherapies in various highly selected patient populations.

OUR PIPELINE

Vigeo's proprietary platform has generated a robust pipeline, including clinical and preclinical programs that target TME.



VigeoTherapeutics.com